Radella reports positive Phase 1a results for MD-18 obesity treatment
Radella Pharmaceuticals’ MD-18 shows promise in Phase 1a results. (Credit: Bruno from Pixabay) Radella Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced topline results from its Phase 1a study of MD-18, an investigational treatment for obesity and diabetes. The study evaluated MD-18’s safety, tolerability, and pharmacokinetics. MD-18 targets protein-tyrosine phosphatase 1B (PTP1B), a therapeutic target supporting […]
